Highest-materiality recent filing
TScan cuts 75% of workforce, pauses Phase 3 ALLOHA-2, refocuses on in vivo solid tumors
Workforce reduction ~75%; ~$4.1M employee-related costs; $55.0M cumulative savings through 2027; cash runway into Q4 2027.
Amgen terminates Crohn's disease collaboration with TScan; effective Nov 10, 2026
Amgen gave notice Aug 12, 2026 to terminate Research Collaboration and License Agreement; effective Nov 10, 2026.
TScan Q2 net loss narrows to $30.4M; first patient dosed in Phase 3 ALLOHA-2 trial
Q2 2026 net loss $30.4M vs $37.0M; revenue $1.1M vs $3.1M, down on Amgen collaboration timing.
TSC-101 Cohort C: 11/14 patients achieved complete donor chimerism; Phase 3 start planned this month
11 of 14 patients achieved complete donor chimerism within ~3 weeks of first TSC-101 infusion; 2 additional patients approaching.
Net loss $23.0M in Q4 2025 vs $35.8M Q4 2024; revenue $2.6M vs $0.7M.
TScan Therapeutics retention program grants cash and RSUs to CEO, CFO, CMO tied to TSC-101 milestone
Board approved retention program for CEO Gavin MacBeath, CFO Jason Amello, and CMO Chrystal Louis.
FDA agrees to pivotal study design for TSC-101 in AML/MDS; trial to start Q2 2026.
TScan Q4 net loss $35.8M; revenue down 90% YoY; heme relapse data positive
Net loss $35.8M in Q4 vs $19.6M YoY; full-year net loss $127.5M vs $89.2M.
Entered securities purchase agreement for pre-funded warrants to purchase 7.5M shares at $4.00 per warrant, gross proceeds ~$30M.
TScan refinances convertible debt with up to $52.5M term loan from Silicon Valley Bank
First tranche of $32.5M drawn at closing; used to retire $17.2M existing convertible debt with K2 HealthVentures plus $2.1M exit fee.
TScan reports positive Phase 1 ALLOHA data; plans registrational trial for TSC-101 in H2 2025
Event-free survival strongly favored treatment arm (HR=0.30, p=0.04); relapse probability trended lower (HR=0.28, p=0.14).
TScan Q3 net loss $29.9M; ALLOHA heme trial shows no relapses in 16 treatment patients
Net loss $29.9M in Q3 2024 vs $23.0M in Q3 2023; revenue $1.0M vs $3.9M.
TScan Q2 net loss $31.7M; revenue falls to $0.5M; RMAT designation for lead candidates
Revenue $0.5M, down from $3.1M in Q2 2023, primarily due to Amgen collaboration timing.
TScan Therapeutics appoints Garry Nicholson to board, Stephen Biggar named chair; Barberich retires
Timothy Barberich resigned as director and Chair effective June 12, 2024; no disagreement cited.
Net loss of $30.1M for Q1 2024 compared to $22.6M in Q1 2023; revenue fell to $0.6M from $6.8M.
TScan Therapeutics prices upsized $150M public offering; provides preliminary cash of $162.8M
Pricing of 2,472,581 shares at $7.13/share and pre-funded warrants for 18,577,419 shares at $7.1299/warrant.
TScan Therapeutics: all 8 heme patients relapse-free >10 months; solid tumor 60% qualify
All 8 TSC-100/101 treated patients remain MRD-negative and relapse-free (median follow-up >10 months); no dose-limiting toxicities.
TScan Q4 net loss $19.6M; all 8 TSC-100/101 patients relapse-free
Q4 revenue $7.2M (up from $3.1M YoY); full-year revenue $21.0M. R&D expenses $22.4M Q4, $88.2M full year.
All 6 evaluable patients treated with TSC-100 or TSC-101 achieved complete donor chimerism and MRD negativity; none of 4 control-arm patients achieved these endpoints.
TScan Therapeutics reports Q3 2023 net loss of $23.0M; cash runway into 2026
Net loss $23.0M in Q3 2023 vs $16.2M in Q3 2022; revenue $3.9M (up from $3.4M) from collaboration.
TScan Q2 net loss $24M, cash $208.8M; heme and solid tumor trials advancing
Net loss of $24.0M in Q2 2023, vs $15.1M in Q2 2022; revenue $3.1M (down from $4.1M).
Brian Silver resigned as CFO, effective July 21, 2023; CEO Gavin MacBeath named interim Principal Financial Officer.
TScan CFO Brian Silver to step down effective July 21, 2023
CFO and Treasurer Brian Silver resigns, effective July 21, 2023, to join an advisory firm in New York.
TScan Therapeutics prices $140M public offering of common stock and pre-funded warrants
Gross proceeds of ~$140M from 22.99M shares at $2.00/share and 47.01M pre-funded warrants at $1.9999 each.
TScan reports preliminary Phase 1 data for TSC-100/101; TSC-101 advances to Dose Level 2
TSC-101 in high-risk MDS patient: 100% donor chimerism, no p53 mutation detected (sensitivity 0.01%), no DLTs.
TScan reports Q1 net loss $22.6M; Amgen partnership adds $30M upfront, extends cash runway
Net loss $22.6M vs $16.2M in Q1 2022; revenue $6.8M, up from $3.0M on Novartis collaboration wind-down.
TScan enters $30M upfront collaboration with Amgen to identify Crohn's disease T-cell targets
TScan receives $30M upfront; eligible for over $500M in development and commercial milestone payments.
TScan CEO David Southwell steps down; Gavin MacBeath named acting CEO
David Southwell resigned as CEO, President, and Board member effective March 27, 2023; no disagreement with company.
TScan Therapeutics reports Q4 net loss of $18.7M; cash $120M funds operations into Q2 2024
Q4 2022 net loss $18.7M vs $14.2M in Q4 2021; FY2022 net loss $66.2M vs $48.6M.
In connection with the Strategic Reorganization, effective as of September 2, 2026 (the “Effective Date”), the employment of Jason A. Amello, the Company’s Chief Financial Officer, and Chrystal Louis, M.D., MPH, the Company’s Chief Medical Officer, was terminated.
In connection with the Strategic Reorganization, effective as of September 2, 2026 (the “Effective Date”), the employment of Jason A. Amello, the Company’s Chief Financial Officer, and Chrystal Louis, M.D., MPH, the Company’s Chief Medical Officer, was terminated.
As of the Effective Date, Gavin MacBeath, Ph.D., the Company’s Chief Executive Officer, assumed the duties of the principal financial officer and principal accounting officer of the Company.
Current member of the Board, Stephen Biggar, M.D., Ph.D., assumed the role of Chairman of the Board, effective as of the Effective Date.
On June 12, 2024 (the “Effective Date”), after the conclusion of the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of TScan Therapeutics, Inc. (the “Company”), Timothy Barberich, a member and Chairman of the Board of Directors (the “Board”) of the Company, tendered his resignation from the Board and Chairman position thereof, effective immediately.
On June 12, 2024, the Board appointed Garry Nicholson to the Board, effective as of the Effective Date.
On January 29, 2024, TScan Therapeutics, Inc. (the “Company”) announced the appointment of Jason A. Amello as Chief Financial Officer, which was approved by the Board of Directors of the Company on January 24, 2024, effective January 29, 2024 (the “Start Date”).
On December 6, 2023, the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “Company”) appointed R. Keith Woods, to the Board, effective December 6, 2023.
replacing Brian Silver, who had previously announced his resignation as Chief Financial Officer of the Company effective July 21, 2023.
appointed Leiden Dworak as Principal Accounting Officer of the Company, effective July 21, 2023
appointed Gavin MacBeath, Ph.D., as the interim Principal Financial Officer of the Company, effective July 21, 2023
On June 27, 2023, Mr. Brian Silver informed TScan Therapeutics, Inc. (the “Company”) of his intent to step down from his roles as Chief Financial Officer and Treasurer of the Company, effective July 21, 2023.
Max materiality 0.90 · Median 0.60 · Most common event other_material